. home.aspx

NEWS

home.aspx
   


Bristol-Myers Squibb, Bayer team up on Opdivo-Stivarga combo in colorectal cancer

July 18, 2019 / Carly Helfand

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo and its bringing in Bayer to help. The two companies, along with Bristol partner Ono Pharmaceutical, have joined forces in a clinical pact to test the immuno-oncology star alongside Bayers Stivarga in patients with microsatellite stable metastatic colorectal cancer, which represents about 95% of cases. The companies stayed tight-lipped on the collaboration’s terms, but they did note that they’ll be plotting an indication-seeking trial for the drug duo. Right now, Opdivo bears a green light to treat a sliver of the colorectal cancer patient population. Nearly two years ago, the FDA gave the treatment a go-ahead in those with microsatellite instability-high (MSI-H) metastatic colorectal cancer, a rare tumor type that makes sufferers less likely to respond to conventional chemo. In the broader colorectal cancer group, though, “I-O monotherapy treatment approaches have sh...